1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
DoD Clinical and Rehabilitative Medicine Research Funding Opportunity (Regenerative Medicine Focused Research Award) is sponsored by Department of Defense (DoD) / Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). This opportunity supports the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NAVREF - DoD Clinical & Rehabilitative Medicine Research Funding Opportunity Promoting Partnerships To Improve Veterans’ Health State of the Science Series NPC Membership & Benefits NPCs: A Unique Public Private Partnership VA Annual NPC Report to Congress NAVREF Advocacy Priorities 2026 NAVREF Conference Agenda Best Practice Consultations DoD Clinical & Rehabilitative Medicine Research Funding Opportunity DoD Clinical & Rehabilitative Medicine Research Funding Opportunity Anonymous member (Administrator) The JPC-8/CRMRP is offering the Regenerative Medicine Focused Research Award (RMFRA) as its next iteration of the Armed Forces Institute of Regenerative Medicine (AFIRM), AFIRM III, in FY19 to continue its effort to support the development of regenerative medicine solutions.
The JPC-8/CRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications for the RMFRA. The FY19 JPC-8/CRMRP Program Announcement and General Application Instructions for the RMRFA mechanism are anticipated to be posted on the Grants. gov website in June 2019.
Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.
Focus Areas and Areas of Encouragement All projects submitted under the FY19 JPC-8/CRMRP RMFRA will be required to address one or both of the following Focus Areas: Peripheral nerve regeneration Skeletal muscle regeneration Efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.
Similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.
The FY19 JPC-8/CRMRP RMFRA Areas of Encouragement include: Immediate reconnection of severed peripheral nerves (e.g., preventing Wallerian degeneration) Regeneration of composite muscle and nerve injuries leading to improved function Regenerative therapies for volumetric muscle loss Preservation of denervated end organs Maintenance of the motor end plate or regeneration of the neuromuscular junction Improving the rate of peripheral nerve regeneration https://cdmrp.
army. mil/pubs/press/2019/19dmrdppreann_jpc8 Regenerative Medicine Focused Research Award (RMFRA) Independent investigators at all academic levels (or equivalent) · Preproposal is required; full application submission is by invitation only. · Accommodates either Single Principal Investigator (PI) or Multiple PI submissions.
All research teams should include highly qualified investigators. Partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.
· Supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (Multiple PI submissions) or through comprehensive projects (Single PI submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury · Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged.
· Research projects should be either advanced preclinical research or early stage clinical trials (Phase 0, I, or IIa) · Applications must address one or both of the FY19 JPC-8/CRMRP RMFRA Focus Areas · Maximum funding of $10,000,000 for total costs (direct plus indirect costs) · Submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.
Submissions with a total of less than the maximum of $10M are encouraged · Maximum period of performance is 5 years usarmy. detrick. medcom-cdmrp.
mbx. cdmrp-public-affairs@mail. mil Powered by Wild Apricot Membership Software
According to the current listing, eligibility includes: Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged. Confirm the full requirements in the official notice before applying.
DoD Clinical and Rehabilitative Medicine Research Funding Opportunity (Regenerative Medicine Focused Research Award) is funded by Department of Defense (DoD) / Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read article